Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 7, 2013

View Archived Issues

Merck & Co. provides pipeline overview in 2012 financial results

BTK inhibitors designed at Novartis

Novartis presents novel HDAC4 inhibitors

Novel platinum complexes developed by Chinese team

Cangene acquires rights to IB-1001

GSK supports AllTrials campaign

Mitsubishi Tanabe's in-house and out-licensed programs advance in third quarter of fiscal 2012

Oncotype DX Colon Cancer test can affect treatment recommendations and costs

Therapeutic cervical cancer vaccine eradicates established tumors in mice

Diagnostics for cancer developed by group of French researchers

The University of Bath designs agents for drug and alcohol abuse

Merck & Co. describes new Trk-A inhibitors

Ability Pharmaceuticals receives grant to develop lipid analogue therapeutic

Summit and Children's National Medical Center form biomarker collaboration for DMD

Autophagy-inducing peptide drug displays antiviral activity

GSK to advance GSK-2586184 into phase II studies

Regen BioPharma files IND for drug-refractory aplastic anemia therapeutic

Phase II trial investigates PC-SOD for idiopathic pulmonary fibrosis in Korea

Seikagaku begins phase II trial for SI-613 in Japan

Biogen acquires full rights to Tysabri

Astellas Pharma profiles pipeline progress of third quarter of fiscal 2012

Seattle Genetics begins two phase I trials of SGN-CD19A

First patient treated in phase I trial of GL-ONC1

Phase II study of Zybrestat plus Avastin passes interim toxicity analysis

Chugai seeks expanded Japanese approval for Herceptin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 12, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...